EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 3558875
• 负责人: LAWRENCE H EINHORN
• 金额: $ 20.86万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-05-01 至 1994-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558875
• 关键词: antineoplastics; autologous transplantation; azacitidine; bladder neoplasm; bleomycin; bone marrow neoplasms; breast neoplasms; cis platinum compound; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cytosine arabinoside; etoposide; flow cytometry; germ cell neoplasms; human subject; human therapy evaluation; lymphocytic leukemia; melanoma; mitoxantrone; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; quality of life; small cell lung cancer; testis neoplasms; thymus neoplasms

The primary goals of the research proposed are to improve medical care, prolong patient survival with optimal achievement in quality of life, and rapidly assimilate data from clinical trials performed within the framework of the efforts of the Eastern Cooperative Oncology Group. Our approach to patient care is enhanced by extensive and organized involvement in additional disciplines; such cooperation is designed to provide patients with neoplastic disease the most promising therapy available. Although we are new members to the Eastern Group, our ultimate contribution can best be anticipated by reflecting on our past record in the Southeastern Cancer Study Group: Indiana University led the SECSG in the accrual of patients on multimodality protocols, and our leadership role was further defined by our achieving the highest patient accession rate within the group for its last two funded years and the exceptional administrative and participatory involvement in committee and protocol responsibilities by our faculty. Our 1987 patient accession total is not reflective of our future accrual rate with ECOG. Of necessity, we are competing scientifically important studies which were begun during our tenure with the SECSG. Of particular note are the extensive small cell lung cancer study (LUN 302) and our investigation of standard versus double dose chemotherapy for testis cancer (GU 303). Both protocols have strong accrual, 94 patients in all. These patient populations will become an additional resource for ECOG studies when LUN 302 and GU 303 have been completed, no later than May 1989. Yet another patient population will become available when our Veterans Administration Hospital completes its Institutional Assurance with the OPRR. Support for both ongoing and new research conducted by Indiana University will enable us to expand our leadership responsibilities within the Eastern Cooperative Oncology Group.

提出的研究的主要目标是改善医疗服务， 延长患者的生存，并在生活质量上取得最佳成就，并且 迅速同化来自在临床试验中进行的数据 东方合作肿瘤学小组努力的框架。 我们的 广泛而有条理的方法可以增强患者护理的方法 参与其他学科；这种合作旨在 为患者提供肿瘤疾病最有前途的疗法 可用的。 尽管我们是东部集团的新成员，但我们 通过反思我们的过去，可以最好地预期最终的贡献 东南癌症研究小组的记录：印第安纳大学领导 多模式方案中患者应计的SECSG，我们的 我们的最高患者进一步定义了领导角色 该小组的最后两个资助年内的加入率， 出色的行政和参与参与委员会以及 我们的教职员工承担方案责任。 我们1987年的患者加入总数并不能反映我们未来的应计 ECOG的速率。 我们必须在科学上竞争至关重要 我们在SECSG任职期间开始的研究。 特别 注意是广泛的小细胞肺癌研究（LUN 302）和我们的 研究睾丸的标准剂量化疗与双剂量化学疗法 癌症（GU 303）。 两种方案都有强大的应计，共有94例患者。 这些患者人群将成为ECOG的附加资源 LUN 302和GU 303完成的研究，不迟于5月 1989年。当我们 退伍军人管理医院完成了机构保证 与OPRR。 支持印第安纳大学正在进行的新研究和新研究 将使我们能够扩大我们的领导责任 东部合作肿瘤学小组。